Dengue: Status of current and under-development vaccines

Marianna Redoni, Sophie Yacoub, Laura Rivino, Daniele Roberto Giacobbe, Roberto Luzzati, Stefano Di Bella

Research output: Contribution to journalReview article (Academic Journal)peer-review

30 Citations (Scopus)
484 Downloads (Pure)


Dengue is an emerging mosquito-borne viral infection with increasing reports of outbreaks. The clinical picture ranges from a benign febrile illness through to severe and potentially fatal manifestations. No specific anti-viral treatment exists, and therapy only consists of supportive care. During the last three decades, several attempts to develop an effective vaccine have been made. The first dengue vaccine to obtain licensure was Dengvaxia, which was authorized in 2015 and is currently available in over 20 countries. Its use has been approved with strict limitations regarding age and serostatus of the recipients, highlighting the necessity for a more safe and efficacious vaccine. At present several vaccine, candidates are undergoing clinical and pre-clinical trials. The most advanced candidates are TDV and TDV 003/005, two live-attenuated vaccines, but another 15 vaccines are under development, introducing novel immunization strategies to the traditional dengue vaccine scenario. This work reviews the current research status on dengue vaccines.

Original languageEnglish
Pages (from-to)e2101
JournalReviews in Medical Virology
Early online date26 Feb 2020
Publication statusE-pub ahead of print - 26 Feb 2020

Bibliographical note

© 2020 John Wiley & Sons, Ltd.


Dive into the research topics of 'Dengue: Status of current and under-development vaccines'. Together they form a unique fingerprint.

Cite this